UK considers new policy on gene edited crops and livestock

January 8, 2021
Some good news: brand-name drug prices continue to fall, and the UK is considering smart, science-based policy on gene edited crops and livestock. We also tell you how you can share uplifting stories about people who are making a positive impact on patients and the…
BIO

Some good news: brand-name drug prices continue to fall, and the UK is considering smart, science-based policy on gene edited crops and livestock. We also tell you how you can share uplifting stories about people who are making a positive impact on patients and the planet. (747 words, 3 minutes, 44 seconds)

 

UK considers new policy on gene edited crops and livestock

 
 

The post-Brexit British government is making way for gene edited crops and livestock—which would bring “widespread benefits to consumers and farmers, including healthier food, environmental improvements, and better animal welfare,” reports The Guardian. Here’s what we know. 

Yesterday, the UK Department for Environment, Food, and Rural Affairs launched a consultation on the regulation of gene editing technologies. They’ll first look at “regulation of gene edited (GE) organisms possessing genetic changes which could have been introduced by traditional breeding,” followed by genetically modified organisms (GMOs), per the announcement.

This is a sharp shift from the strict EU rules, which “make gene editing for crops and livestock almost impossible” by regulating GE organisms the same as GMOs, which are essentially banned, explains The Guardian

What they’re saying: “Gene editing has the ability to harness the genetic resources that mother nature has provided, in order to tackle the challenges of our age. This includes breeding crops that perform better, reducing costs to farmers and impacts on the environment, and helping us all adapt to the challenges of climate change,” said UK Secretary of State for Environment, Food, and Rural Affairs George Eustice.

We agree. Gene editing has potential to "reap big benefits for both human health and the health of our environment," as Innovature put it. Now, it's time for smart, science-driven policy around the world that recognizes this. 

Want to know more about the science of gene editing?

LISTEN: BIO’s Dr. Clint Nesbitt and the American Seed Trade Association’s Dr. Fan-Li Chou discussed on a recent episode of the Illinois Farm Bureau podcast

READ: Check out this list of 20 benefits of gene editing plus more content about the science behind gene edited products at www.innovature.com.   

 
 
 
Twitter
 
LinkedIn
 
Facebook
 
 

I am BIO: Inspiring Your 2021

I am inspiring. I am changing the world. I am BIO.
 
 

Exactly seven months ago, we launched the I am BIO campaign to tell the story of the biotechnology industry through the eyes of people making an impact every day.

If you need a feel-good story this week, head over to www.bio.org/iambio to meet the scientists, doctors, patients, investors, researchers, and advocates who are advancing innovations that cure patients, protect our planet, and nourish humanity. (P.S. Visit All Videos to search or filter by category.) 

Want to participate this year year? Here are the new categories we’re planning to highlight in 2021:

  • COVID-19
  • Patient Advocacy
  • Health
  • Academia
  • Agricultural Biotechnology
  • Environmental Biotechnology
  • Animal Biotechnology
  • Women in Biotechnology
  • Investor
  • Diversity and Inclusion

Visit www.bio.org/iambio and get inspired.

 
 
 
Twitter
 
LinkedIn
 
Facebook
 
 

New data on brand-name drug prices

 
 

“Surprise! Brand-Name Drug Prices Fell (Again) in 2020.” That’s the headline of a new blog post by Dr. Adam J. Fein of Drug Channels. Here's more on the data.

First, two terms you should know: list price and net price. To put it simply, the list price is established by the manufacturer of the drug, while the net price “equals the actual revenues that a manufacturer earns from a drug after rebates, discounts, and other reductions,” explains Dr. Fein.

“List-price growth has dropped significantly,” he said. “From 2010 to 2015, growth in list prices was increasing by 10% to 15%. Growth has slowed sharply over the past five years, from 13.5% in 2014 to 4.2% through the first three quarters of 2020.”

Meanwhile, “brand-name drug net prices dropped for the third consecutive year” in 2020, by -2.2%. “The gross-to-net gap in prices was -6.4%.”

 
Brand-Name Drugs, List vs. Net Price Growth, 2014 to 2020 (via Drug Channels)
 

Why it matters: “Brand-name drug prices continue to decline while the prices of other healthcare products and services continue to rise. Politicians, journalists, and academics who focus on list prices distort the truth about drug prices,” concludes Dr. Fein.

This is in line with recent data from the Center for Medicare and Medicaid (CMS), which found that hospital care and physician and clinical services (like visits to the doctor’s office) were the largest categories of health care spending, while prescription drug prices continue to decline.

We’ll say it again: If policymakers are serious about reducing out-of-pocket health care costs, we need systemic and bipartisan reforms that address legitimate concerns about U.S. health insurance and delivery, including the affordability and accessibility of medicines.

 

More Health Care News:

Reuters: Pfizer-BioNTech vaccine appears effective against mutation in new coronavirus variants
“The not-yet peer reviewed study by Pfizer and scientists from the University of Texas Medical Branch indicated the vaccine was effective in neutralizing virus with the so-called N501Y mutation of the spike protein.”

 
Twitter
 
LinkedIn
 
Facebook
 
 
BIO Beltway Report
BIO Beltway Report
 
Paragraph (sm) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis sample link.
 

President Trump’s Friday: Last night, he released a video on his recently reinstated Twitter account condemning the riots at the U.S. Capitol and saying he will focus on a “smooth, orderly, and seamless transition of power.” Meanwhile, two Cabinet secretaries have resigned: Transportation Secretary Elaine Chao and Education Secretary Betsy DeVos

President-elect Biden’s Friday: He’s selected Rhode Island Gov. Gina Raimondo for Commerce secretary and Boston Mayor Marty Walsh for Labor secretary

What’s Happening on Capitol Hill: Calls for President Trump’s removal are growing louder. Capitol Police Chief Steven Sund is resigning.

 
 
Paragraph (normal) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus sample link.
 
Twitter
 
LinkedIn
 
Facebook